отрицательные отзовы о препаратеvery hard

I.: Do you expect a rush of people switching from say, for example, c

J.J.: What we have said is that it will at least be a blockbuster, which is $1 billion in sales. But the total MS market globally is over $10 billion. And within the U.S. it's about half of that, so we feel fairly confident that it will at least be a $1 billion drug for us.

I.: You want to make your money back...totally understandable. That's the capitalist system. I have seen analyst numbers that put this at being about a billion dollars in sales a year for your company. Does that sound about right?

J.J..: We're going to price Gilenya competitive with the other MS compounds. Part of it is that we have had this drug in development for over 10 years. We have spent over $1 billion in total development costs to bring it to market. Therefore, obviously the way that pharmaceutical companies and any company that's really invested in research recovers the cost of that investment is by pricing it competitively to what's on the market.

I.: And when you look at this drug, the pricing...I haven't heard anything on the pricing yet. Now the prices of most MS drugs have skyrocketed over the past 10 years. How will you price this?

J.J.: It does. So if you think about MS, it's an autoimmune disease in which the body's own immune system starts to attack the protective coating round the nerve fibers that transmit signals to other parts of the body. And what Gilenya does is it slows that autoimmune response.

I.: So it's not just easing the pain of MS, it actually slows the progression?

J.J..: No, and we get comments all the time from patients who say they don't like that. So this is the first oral therapy. But also, it has best in class efficacy. So we were able to demonstrate a 52% reduction in relapse rate versus the current standard of care in MS.

Joe Jimenez: I'll tell you the FDA's approval of Gilenya really represents a breakthrough in the treatment for MS. Not only is it the first oral therapy for MS patients. So typically, today, a MS patient has to either inject or infuse the medicine...

Interviewer: This is your first interview since the FDA approved the first oral therapy here in the United States for Multiple Sclerosis (MS) Gilenya. How much of a game changer is this and why?

Генеральный директор фармкомпании Новартис (Novartis) рассказывает о недавнем одобрении их препарата Гиления (Gilenya) американскими регуляторными органами, а также о перспективах развития фарминдустрии США после окончания действия режима пониженного налогообложения «эпохи Буша» для американского среднего класса. 

   Количество просмотров:

10:08   27 октября 2010

Видеоинтервью: Джо Хименес, генеральный директор Новартис, о новом препарате для лечения рассеянного склероза и о перспективах развития компании

     9 12    

Подписаться на рассылку

Информационный портал для профессионалов фармацевтической и медицинской отраслей Украины, России и других стран.

Информационный портал для профессионалов фармацевтической и медицинской отраслей Украины, России и других стран.        

Видеоинтервью: Джо Хименес, генеральный директор Новартис, о новом препарате для лечения рассеянного склероза и о перспективах развития компании